Phillips 66 Swings to Q4 Adjusted Loss-March 2024-www.financetom.com

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Phillips 66 Swings to Q4 Adjusted Loss

Jan 31, 2025 4:58 AM

07:26 AM EST, 01/31/2025 (MT Newswires) -- Phillips 66 (PSX) reported Friday it swung to a Q4 adjusted loss of $0.15 per share from adjusted earnings of $3.09 a year earlier.

Analysts polled by FactSet expected a loss of $0.03.

Previous page： Wells Fargo No Longer Under Investigation from 18 States After Abandoning ESG Policies Next page： TikTok Shop steps up Europe expansion with US future unclear

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Wells Fargo No Longer Under Investigation from 18 States After Abandoning ESG Policies

Mar 27, 2025

01:35 PM EDT, 03/27/2025 (MT Newswires) -- Wells Fargo ( WFC ) is no longer under investigation by attorneys general from 18 states for possible violations of antitrust and consumer protection laws after it abandoned environmental, social, and governance policies, Tennessee Attorney General Jonathan Skrmetti said in a statement Thursday. The coalition of state prosecutors alleged that Wells Fargo (...

TikTok Shop steps up Europe expansion with US future unclear

Mar 27, 2025

LONDON (Reuters) - E-commerce platform TikTok Shop said it will launch to users in France, Germany, and Italy on Monday, expanding its reach further into Europe even as TikTok faces being shut down in the U.S. if Chinese owner ByteDance does not find an American buyer. The shopping arm of social media app TikTok has been available in the UK...

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease

Mar 27, 2025

01:33 PM EDT, 03/27/2025 (MT Newswires) -- Regulus Therapeutics ( RGLS ) said Thursday it has completed its phase 1b clinical trial of farabursen for the treatment of autosomal dominant polycystic kidney disease, with full data from the fourth cohort confirming the 300mg fixed dose selection to achieve optimal kidney exposure. The company said that over four months, patients treated...

Novo shares on track for biggest monthly fall since 2002, investor worries grow

Mar 27, 2025

LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly. The Danish drugmaker's launch of weight-loss injection Wegovy propelled it to become Europe's most valuable company by...